At Aicella, we’re at the forefront of revolutionizing CAR-T therapy development. The soaring demand for personalized cancer treatments has propelled us to create innovative tools that streamline processes, reduce bottlenecks, and significantly enhance patient outcomes. Our InsightsTM data dashboard stands as a beacon of efficient process design and analysis, catering to the evolving needs of the global CAR-T therapy market.
On April 27 Join ISCT subject matter experts to address the challenges associated with scaling cryopreservation processes on the path to commercialization.
Speakers will share insights and critical perspectives on technology innovations, allogeneic therapy workflows, and key considerations for autologous manufacturing.
Join the discussion for an opportunity to...
- Recognize critical cryopreservation challenges across autologous and allogeneic therapies
- Identify available technology used to scale cryopreservation process - Interpret key variables and how they impact product quality and process reproducibility
- Understand implementation challenges
Learn more and register today: https://buff.ly/w1IzQHA
Chair:
Sean Werner, PhD
Speakers:
Camillo Ricordi, MD, FNAI
Scott B. Reeves Reeves, MS
Lothar Lauterboack, PhD
🚀 Unlocking Scalable Cell Therapy Manufacturing with AI
Excited to share our work from AiCella, Inc. on AI-enabled data harmonization and predictive modeling for cell therapy manufacturing.
Cell and gene therapy manufacturing continues to face major challenges:
❗ High variability
❗ Costly production cycles
❗ Fragmented, siloed data
❗ Labor-intensive QC
At AiCella, we’re tackling this head-on with our Insights™ AI platform, which is designed to unify complex manufacturing data streams and transform them into actionable intelligence.
🔬 What we demonstrated:
Integration of multimodal data (process parameters, QC, microscopy, batch records)
Identification of key drivers of patient response across 128 CAR-T batches
Use of explainable AI (LIME, ROC, tree-based models) to move beyond black-box predictions
Feature association mapping to uncover hidden process relationships
Early evidence that AI can reduce failures, shorten timelines, and lower COGS
📊 One of the most exciting findings:
AI models highlighted oxygen dynamics (DO, pO₂) and early process conditions (Day 1 pH, expansion) as critical determinants of manufacturing success — reinforcing the importance of early, data-driven intervention.
💡 Why this matters:
This work reinforces a key truth in CGT, which is that AI is only as powerful as the data foundation beneath it. Standardization, harmonization, and structured data capture are no longer optional; they are prerequisites for scalable, GMP-ready AI.
🔗 We believe this represents a meaningful step toward:
➡️ Real-time manufacturing intelligence
➡️ Predictive quality control
➡️ Digital twin-enabled process optimization
And ultimately… more reliable therapies reaching patients faster.
If you're working in CGT manufacturing, automation, or data infrastructure, let’s connect. The future of this industry will be built on data + AI + collaboration.
#CellTherapy#GeneTherapy#Biomanufacturing#AI#MachineLearning#CGT#DigitalTransformation#ISCT2026#AdvancedTherapiesAiCella
AiCella’s CEO, Geoffrey Stephens, PhD, MBA, will be joining an upcoming panel at the Cell Therapy & CMC Manufacturing Forum 2026 to share real-world insights from the front lines of building a company in the CGT space.
🗓 April 30, 2026
🕘 9:15 AM – 10:45 AM
📍 Open Biopharma | Carlsbad, CA
This session will go beyond the headlines to explore the real challenges CEOs face in early-stage biotech, including:
🔹 Navigating shifting investor landscapes
🔹 Building strategic partnerships in a complex ecosystem
🔹 Balancing innovation with regulatory and manufacturing realities
🔹 Scaling teams, data, and infrastructure simultaneously
🔹 Turning promising science into viable, investable platforms
At AiCella, Geoffrey is leading efforts to integrate AI/ML into cell therapy manufacturing, tackling some of the toughest bottlenecks in the industry—and experiencing firsthand the unique pressures that come with building a venture at the intersection of biotech and AI.
💡 If you’re a founder, operator, investor, or aspiring biotech leader, this will be a candid and highly relevant discussion.
Let’s connect if you’ll be attending!
Please click on this registration link to see details of the hashtag
#agenda and line-up of
#panelists:
https://lnkd.in/grizqsY3#Biotech#Startups#CEO#Leadership#CellTherapy#GeneTherapy#CGT#AI#MachineLearning#Biomanufacturing#Entrepreneurship#OpenBiopharma#Carlsbad
AiCella is addressing one of the most pressing challenges in cell and gene therapy (CGT): the inability to reliably scale manufacturing while controlling cost and variability.
At its core, the problem is clear: current CAR-T manufacturing workflows are expensive, inconsistent, and prone to failure. These limitations stem from fragmented data, limited process understanding, and the complexity of biological systems. AiCella positions its Insights™ AI/ML platform as a solution to this “scaling crisis,” offering a unified, data-driven approach to manufacturing optimization.
The platform integrates multiple critical data streams, process parameters, quality control (QC) measurements, and microscopy into a single, searchable and analyzable framework. By bringing together structured and unstructured data, Insights™ enables a more holistic understanding of how manufacturing conditions influence outcomes. This unified data foundation is further enhanced by retrieval-augmented generation (RAG), which provides context-aware, document-linked decision support. In practice, this means operators and scientists can move beyond intuition or siloed data toward evidence-based, explainable decision-making.
The impact of this approach is demonstrated through predictive modeling performance. Using ensemble machine learning methods such as AdaBoost, the platform achieved perfect accuracy in identifying parameters linked to patient response in the dataset presented. Comparative modeling shows consistently strong performance across algorithms, with high accuracy, ROC AUC, and F1 scores, highlighting both robustness and reliability.
Importantly, the platform does not function as a “black box.” Through interpretability tools such as LIME analysis, AiCella identifies key drivers of success in CAR-T manufacturing. In this case, oxygen levels and early pH stability emerge as critical variables influencing outcomes. This level of insight transforms AI from a predictive tool into a mechanistic discovery engine—one that can guide process optimization and standardization.
Looking forward, the integration of these capabilities supports the development of digital twin models, which are virtual representations of manufacturing processes that enable simulation, prediction, and prescriptive optimization. These digital twins can be used to reduce failure rates, improve consistency, and ultimately lower the cost of goods in CGT manufacturing.
In summary, AiCella’s Insights™ platform represents a shift from reactive to predictive and prescriptive manufacturing. By combining unified data integration, high-performance machine learning, explainability, and digital twin applications, it provides a scalable path toward more efficient, reliable, and accessible cell therapies.
AiCella’s CEO, Geoffrey Stephens, PhD, MBA, will be joining an upcoming panel at the Cell Therapy & CMC Manufacturing Forum 2026 to share real-world insights from the front lines of building a company in the CGT space.
🗓 April 30, 2026
🕘 9:15 AM – 10:45 AM
📍 Open Biopharma | Carlsbad, CA
This session will go beyond the headlines to explore the real challenges CEOs face in early-stage biotech, including:
🔹 Navigating shifting investor landscapes
🔹 Building strategic partnerships in a complex ecosystem
🔹 Balancing innovation with regulatory and manufacturing realities
🔹 Scaling teams, data, and infrastructure simultaneously
🔹 Turning promising science into viable, investable platforms
At AiCella, Geoffrey is leading efforts to integrate AI/ML into cell therapy manufacturing, tackling some of the toughest bottlenecks in the industry—and experiencing firsthand the unique pressures that come with building a venture at the intersection of biotech and AI.
💡 If you’re a founder, operator, investor, or aspiring biotech leader, this will be a candid and highly relevant discussion.
Let’s connect if you’ll be attending!
Please click on this registration link to see details of the #agenda and line-up of #panelists:
https://lnkd.in/grizqsY3#Biotech#Startups#CEO#Leadership#CellTherapy#GeneTherapy#CGT#AI#MachineLearning#Biomanufacturing#EntrepreneurshipAiCella#OpenBiopharma#Carlsbad
🚀 AiCella at Festival of Biologics 2026 — Let’s Connect in San Diego!
AiCella’s CEO, Geoffrey Stephens, PhD, MBA, will be attending the Festival of Biologics at the San Diego Convention Center on March 4–5, 2026 — joining global leaders advancing the future of biologics, cell & gene therapy, and AI-enabled biomanufacturing.
As the industry moves toward data-driven development and intelligent manufacturing, conversations around AI, process insight, and scalable advanced therapies have never been more important. AiCella is excited to engage with innovators working to transform how biologics and cell therapies are developed, manufactured, and delivered to patients.
📍 Attending Festival of Biologics?
Let’s connect to discuss:
✅ AI-driven manufacturing optimization
✅ In-process analytics & QC intelligence
✅ Data infrastructure for next-generation therapies
✅ Collaborative opportunities across CGT & biologics
If you’ll be in San Diego, reach out or stop Geoff to say hello — we’re always excited to meet partners, collaborators, and forward-thinking builders in the space.
#FestivalOfBiologics#Biologics#CellAndGeneTherapy#AIinBiotech#Biomanufacturing#AdvancedTherapies#SanDiegoBiotechAiCella#CGT#LifeSciences
What a fantastic conversation at #ATW26 during the panel “From Bottleneck to Breakthrough: QC’s Automated Evolution"!
AiCella’s CEO, Geoffrey Stephens, PhD, MBA, joined an outstanding group of experts to tackle one of the biggest challenges in advanced therapy manufacturing: how QC evolves from workflow automation into truly AI-integrated systems.
Huge thanks to Invetech, our incredible panelists Yu-Wen Edith Chang, Félix A MONTERO-JULIAN PhD, Matt Yeung, and our moderator Michelle Duquette, PhD, for bringing energy, real-world perspective, and forward-thinking insights to the discussion.
Some standout takeaways:
• Real COGS impact comes from smart, targeted automation; not automating for automation’s sake
• Workflow automation boosts consistency, but platform redesign unlocks real speed and deployment gains
• Strong data infrastructure is the engine behind everything that follows
• Real-time QC feedback can transform manufacturing, if integration is done right
• AI becomes powerful only after digitization and connectivity are in place
Whether you’re scaling clinical programs or running commercial manufacturing, the roadmap is clear: automate → redesign → integrate → enable AI.
Grateful to Invetech and the ATW organizing team for making this high-energy, high-impact conversation possible and to everyone who joined us. Excited to keep pushing QC innovation forward.
#CellTherapy#GeneTherapy#QCAutomation#Manufacturing#ATW26
Excited to share a quick reminder that AiCella's CEO, Geoffrey Stephens, PhD, MBA, will be speaking at Advanced Therapies Week 2026 on February 10th at the San Diego Convention Center.
🧬 Breakfast Session: From Bottleneck to Breakthrough: QC’s Automated Evolution
🕗 Feb 10 — 8:00 AM PT
📍 Theatre 2
🤝 Hosted by Invetech
The session will explore how AI and automation are reshaping QC and in-process analytics in cell and gene therapy manufacturing — where practical automation helps first, and AI amplifies impact by turning complex process data into actionable insight.
If you’re attending ATW, we’d love to connect. Please stop by, say hello, and join the discussion on how smarter data use can accelerate advanced therapy manufacturing.
InvetechAiCella#ATW2026#CellTherapy#GeneTherapy#AIinBiotech#CGT#ManufacturingInnovation
